StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Gain Therapeutics's price to book ratio was 4.3× on Nov 11, 2026, against 21.3× a year earlier. Over the last 5 years it ranged from 1.1× to 21.3×, with a median of 4.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.3×−15.3
2025Dec 31, 202519.6×+13.3
2024Dec 31, 20246.3×+0.6
2023Dec 29, 20235.7×+4.1
2022Dec 30, 20221.6×−0.1
2021Dec 31, 20211.7×–

More Gain Therapeutics figures

See a number that looks wrong?